Logo image of CNS

COHEN & STEERS INC (CNS) Stock Fundamental Analysis

USA - NYSE:CNS - US19247A1007 - Common Stock

71.34 USD
+0.63 (+0.89%)
Last: 10/24/2025, 8:16:40 PM
71.34 USD
0 (0%)
After Hours: 10/24/2025, 8:16:40 PM
Fundamental Rating

5

Overall CNS gets a fundamental rating of 5 out of 10. We evaluated CNS against 235 industry peers in the Capital Markets industry. CNS scores excellent on profitability, but there are some minor concerns on its financial health. While showing a medium growth rate, CNS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

CNS had positive earnings in the past year.
CNS had a negative operating cash flow in the past year.
Each year in the past 5 years CNS has been profitable.
CNS had a positive operating cash flow in each of the past 5 years.
CNS Yearly Net Income VS EBIT VS OCF VS FCFCNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

1.2 Ratios

CNS has a better Return On Assets (21.59%) than 98.74% of its industry peers.
CNS has a better Return On Equity (30.67%) than 95.38% of its industry peers.
The Return On Invested Capital of CNS (25.18%) is better than 98.32% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CNS is significantly above the industry average of 7.62%.
Industry RankSector Rank
ROA 21.59%
ROE 30.67%
ROIC 25.18%
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
CNS Yearly ROA, ROE, ROICCNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

1.3 Margins

CNS's Profit Margin of 29.82% is fine compared to the rest of the industry. CNS outperforms 74.79% of its industry peers.
In the last couple of years the Profit Margin of CNS has declined.
With a decent Operating Margin value of 33.62%, CNS is doing good in the industry, outperforming 62.18% of the companies in the same industry.
CNS's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 88.71%, CNS belongs to the best of the industry, outperforming 92.86% of the companies in the same industry.
CNS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 33.62%
PM (TTM) 29.82%
GM 88.71%
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
CNS Yearly Profit, Operating, Gross MarginsCNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, CNS has more shares outstanding
The number of shares outstanding for CNS has been increased compared to 5 years ago.
There is no outstanding debt for CNS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CNS Yearly Shares OutstandingCNS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CNS Yearly Total Debt VS Total AssetsCNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 11.08 indicates that CNS is not in any danger for bankruptcy at the moment.
CNS has a Altman-Z score of 11.08. This is amongst the best in the industry. CNS outperforms 94.54% of its industry peers.
There is no outstanding debt for CNS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 11.08
ROIC/WACCN/A
WACCN/A
CNS Yearly LT Debt VS Equity VS FCFCNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.3 Liquidity

CNS has a Current Ratio of 0.87. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
CNS has a worse Current ratio (0.87) than 63.45% of its industry peers.
A Quick Ratio of 0.87 indicates that CNS may have some problems paying its short term obligations.
With a Quick ratio value of 0.87, CNS is not doing good in the industry: 63.03% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.87
Quick Ratio 0.87
CNS Yearly Current Assets VS Current LiabilitesCNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

6

3. Growth

3.1 Past

CNS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.87%, which is quite good.
Measured over the past 5 years, CNS shows a small growth in Earnings Per Share. The EPS has been growing by 2.50% on average per year.
The Revenue has grown by 11.26% in the past year. This is quite good.
The Revenue has been growing slightly by 4.72% on average over the past years.
EPS 1Y (TTM)8.87%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%5.19%
Revenue 1Y (TTM)11.26%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%6.39%

3.2 Future

CNS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.06% yearly.
The Revenue is expected to grow by 8.09% on average over the next years. This is quite good.
EPS Next Y4.56%
EPS Next 2Y8.74%
EPS Next 3Y8.1%
EPS Next 5Y13.06%
Revenue Next Year7.44%
Revenue Next 2Y8.98%
Revenue Next 3Y7.58%
Revenue Next 5Y8.09%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CNS Yearly Revenue VS EstimatesCNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
CNS Yearly EPS VS EstimatesCNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1 2 3 4 5

2

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 23.24, the valuation of CNS can be described as rather expensive.
Compared to the rest of the industry, the Price/Earnings ratio of CNS indicates a slightly more expensive valuation: CNS is more expensive than 61.34% of the companies listed in the same industry.
CNS's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.89.
A Price/Forward Earnings ratio of 20.59 indicates a rather expensive valuation of CNS.
The rest of the industry has a similar Price/Forward Earnings ratio as CNS.
CNS's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.99.
Industry RankSector Rank
PE 23.24
Fwd PE 20.59
CNS Price Earnings VS Forward Price EarningsCNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CNS is valued a bit cheaper than the industry average as 75.21% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 18.26
CNS Per share dataCNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8 10

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of CNS may justify a higher PE ratio.
PEG (NY)5.09
PEG (5Y)9.3
EPS Next 2Y8.74%
EPS Next 3Y8.1%

4

5. Dividend

5.1 Amount

CNS has a Yearly Dividend Yield of 3.51%.
CNS's Dividend Yield is comparable with the industry average which is at 8.34.
CNS's Dividend Yield is rather good when compared to the S&P500 average which is at 2.31.
Industry RankSector Rank
Dividend Yield 3.51%

5.2 History

The dividend of CNS decreases each year by -7.12%.
CNS has been paying a dividend for at least 10 years, so it has a reliable track record.
The dividend of CNS decreased in the last 3 years.
Dividend Growth(5Y)-7.12%
Div Incr Years2
Div Non Decr Years2
CNS Yearly Dividends per shareCNS Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1 2 3

5.3 Sustainability

76.12% of the earnings are spent on dividend by CNS. This is not a sustainable payout ratio.
DP76.12%
EPS Next 2Y8.74%
EPS Next 3Y8.1%
CNS Yearly Income VS Free CF VS DividendCNS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
CNS Dividend Payout.CNS Dividend Payout, showing the Payout Ratio.CNS Dividend Payout.PayoutRetained Earnings

COHEN & STEERS INC

NYSE:CNS (10/24/2025, 8:16:40 PM)

After market: 71.34 0 (0%)

71.34

+0.63 (+0.89%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)10-16 2025-10-16/amc
Earnings (Next)01-20 2026-01-20/amc
Inst Owners60.28%
Inst Owner Change-0.19%
Ins Owners22.51%
Ins Owner Change-0.25%
Market Cap3.64B
Revenue(TTM)552.79M
Net Income(TTM)162.12M
Analysts48
Price Target79.56 (11.52%)
Short Float %7.47%
Short Ratio7.21
Dividend
Industry RankSector Rank
Dividend Yield 3.51%
Yearly Dividend2.39
Dividend Growth(5Y)-7.12%
DP76.12%
Div Incr Years2
Div Non Decr Years2
Ex-Date08-11 2025-08-11 (0.62)
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-3.28%
Min EPS beat(2)-4.27%
Max EPS beat(2)-2.29%
EPS beat(4)0
Avg EPS beat(4)-2.29%
Min EPS beat(4)-4.27%
Max EPS beat(4)-0.35%
EPS beat(8)2
Avg EPS beat(8)-1.05%
EPS beat(12)5
Avg EPS beat(12)0.61%
EPS beat(16)9
Avg EPS beat(16)2.23%
Revenue beat(2)1
Avg Revenue beat(2)0.36%
Min Revenue beat(2)-1.18%
Max Revenue beat(2)1.91%
Revenue beat(4)2
Avg Revenue beat(4)-1.1%
Min Revenue beat(4)-11.33%
Max Revenue beat(4)6.21%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.09%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.27%
EPS NY rev (1m)-0.87%
EPS NY rev (3m)-0.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.35%
Revenue NY rev (3m)1.4%
Valuation
Industry RankSector Rank
PE 23.24
Fwd PE 20.59
P/S 6.69
P/FCF N/A
P/OCF N/A
P/B 6.88
P/tB 7.16
EV/EBITDA 18.26
EPS(TTM)3.07
EY4.3%
EPS(NY)3.46
Fwd EY4.86%
FCF(TTM)-2.4
FCFYN/A
OCF(TTM)-2.28
OCFYN/A
SpS10.66
BVpS10.36
TBVpS9.97
PEG (NY)5.09
PEG (5Y)9.3
Graham Number26.75
Profitability
Industry RankSector Rank
ROA 21.59%
ROE 30.67%
ROCE 32.81%
ROIC 25.18%
ROICexc 30.38%
ROICexgc 34.72%
OM 33.62%
PM (TTM) 29.82%
GM 88.71%
FCFM N/A
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
ROICexc(3y)52.58%
ROICexc(5y)66.96%
ROICexgc(3y)63.61%
ROICexgc(5y)82.87%
ROCE(3y)36.88%
ROCE(5y)49.77%
ROICexgc growth 3Y-36.94%
ROICexgc growth 5Y-14.2%
ROICexc growth 3Y-34.4%
ROICexc growth 5Y-13.57%
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
F-Score5
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 55.86%
Cap/Sales 1.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.87
Quick Ratio 0.87
Altman-Z 11.08
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)429.54%
Cap/Depr(5y)277.84%
Cap/Sales(3y)4.88%
Cap/Sales(5y)3.14%
Profit Quality(3y)59.63%
Profit Quality(5y)81.14%
High Growth Momentum
Growth
EPS 1Y (TTM)8.87%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%5.19%
EPS Next Y4.56%
EPS Next 2Y8.74%
EPS Next 3Y8.1%
EPS Next 5Y13.06%
Revenue 1Y (TTM)11.26%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%6.39%
Revenue Next Year7.44%
Revenue Next 2Y8.98%
Revenue Next 3Y7.58%
Revenue Next 5Y8.09%
EBIT growth 1Y16.09%
EBIT growth 3Y-12.76%
EBIT growth 5Y1.55%
EBIT Next Year17.56%
EBIT Next 3Y18.41%
EBIT Next 5Y14.36%
FCF growth 1Y-196.88%
FCF growth 3Y-29.26%
FCF growth 5Y-9.31%
OCF growth 1Y-177.85%
OCF growth 3Y-26.44%
OCF growth 5Y-7.32%

COHEN & STEERS INC / CNS FAQ

What is the ChartMill fundamental rating of COHEN & STEERS INC (CNS) stock?

ChartMill assigns a fundamental rating of 5 / 10 to CNS.


Can you provide the valuation status for COHEN & STEERS INC?

ChartMill assigns a valuation rating of 2 / 10 to COHEN & STEERS INC (CNS). This can be considered as Overvalued.


Can you provide the profitability details for COHEN & STEERS INC?

COHEN & STEERS INC (CNS) has a profitability rating of 7 / 10.


What are the PE and PB ratios of COHEN & STEERS INC (CNS) stock?

The Price/Earnings (PE) ratio for COHEN & STEERS INC (CNS) is 23.24 and the Price/Book (PB) ratio is 6.88.


What is the expected EPS growth for COHEN & STEERS INC (CNS) stock?

The Earnings per Share (EPS) of COHEN & STEERS INC (CNS) is expected to grow by 4.56% in the next year.